Beroni Group Limited Latest Clinical Study of SARS-CoV-2 Antigen Test Kit

Sydney, Australia (ABN Newswire) - Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, announced the latest clinical study of its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) demonstrated an overall sensitivity of 95% and specificity of 100%.

The clinical study was conducted with 70 subjects providing 105 true-positive specimens and 105 true-negative specimens. The results for the different types of swab sampling are as follows:

- Nasal sampling - sensitivity 92%; specificity 100%

- Nasopharyngeal sampling - sensitivity 97%; specificity 100%

- Oropharyngeal sampling - sensitivity 95%; specificity 100%

The report also showed that in the interference experiment, 8 interfering substances such as Tobramycin and Hemoglobin were not found to affect the results of the detection of SARS-CoV-2 in human nasal cavity, nasopharyngeal and oropharyngeal swab specimens. In the cross-reaction experiment, the researchers selectively evaluated the cross-reactivity of 9 pathogens including rhinovirus and adenovirus when using the product to test SARS-CoV-2, and no cross-reactivity with the above-mentioned pathogens was observed. In the hook effect experiment, when using media such as HM contaminated by SARS-CoV-2 "GC2020/1" strain with a high concentration (maximum concentration available), no hook effect was observed and in the repeatability experiment, the product was used to test positive and negative clinical specimens, and the reproducibility (repeatability) is 100%.

Beroni Group's SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) received CE certification in December 2020 and was granted authorization for export in April 2021. The product can be used for in vitro qualitative auxiliary detection of SARS-CoV-2 antigen specimens and is for professional use only.

"We are encouraged by the latest clinical report. The experimental results show that the SARS-CoV- 2 Antigen Test Kit demonstrated a high level of accuracy. This product is a simple, convenient rapid test kit, and the test results can be obtained within 10 minutes," commented Jacky Zhang, Chairman and CEO of Beroni Group. "Beroni is dedicated to the global fight against the COVID-19 virus. Apart from this product, Beroni's SARS-CoV-2 IgG/IgM Antibody Detection Kit has been exported to Britain, Japan and other countries."



About Beroni Group Limited:  

Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.



Source:
Beroni Group Limited



Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BNIGF@dgipl.com

News Provided by ABN Newswire via QuoteMedia

The Conversation (0)
B2Gold Corp.

B2Gold Corp.

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other significant assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into a global market. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; other mineral properties; and corporate and other. It generates maximum revenue from the Fekola mine segment in Mali.

Barrick Is Now 'B' on the NYSE

Barrick Mining Corporation (NYSE:B)(TSX:ABX) is now trading under the single-letter ticker symbol ‘B' on the New York Stock Exchange, reinforcing the Company's position as a global gold and copper mining leader.

In celebration of this milestone, Barrick president and chief executive Mark Bristow rang The Opening Bell® at the NYSE this morning.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Abcourt Intersects 24.3 g/t Over 1.9 m Including 41.9 g/t Over 0.6 m in the 785N Zone and Provides an Update on Its Sleeping Giant Activities

Abcourt Mines Inc. ("Abcourt" or the "Corporation") (TSX Venture: ABI) (OTCQB: ABMBF) is pleased to report new drilling results and an update on its activities at the Sleeping Giant mine.

In 2025, Abcourt completed 36 underground drill holes totaling 5,632 meters. Of these holes, seven target the 785N zone and the underlying areas for a total of 3,316 meters. This 785N zone is in a new sector to the east and at depth of the developed sectors of the mine. After releasing the results of two of these holes earlier this year, Abcourt is today releasing the results of two more holes, 78-888 and 78-890.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×